Optimi Health Corp. News Releases

Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date

Tue, 26 May 2026 07:00:00 -0400

The 6% naturally derived extract is set to be encapsulated for use in patients suffering from treatment-resistant depression under Australia's Authorised Prescriber Scheme, where no serious adverse events have been reported as of December 2025 Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced...

Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering

Thu, 21 May 2026 13:07:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today closed its previously announced underwritten public offering (the "Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company issued 2,400,000 common shares at a price of...

Optimi Health gibt Preisfestsetzung für überzeichnetes öffentliches Angebot in Höhe von 15 Mio. US-$ und Nasdaq-Uplisting bekannt

Wed, 20 May 2026 08:00:00 -0400

Stammaktien werden am Nasdaq Capital Market unter dem Symbol "OPTH" gehandelt Vancouver, British Columbia--(Newsfile Corp. - Mittwoch, 20. Mai 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (das "Unternehmen" oder "Optimi"), ein pharmazeutisches Unternehmen im kommerziellen Stadium mit Fokus auf die Herstellung und den Vertrieb fertiger psychedelischer Arzneimittelprodukte, gab heute die Preisfestsetzung seines gezeichneten öffentlichen Angebots (das "Angebot") im Zusammenhang...

Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting

Wed, 20 May 2026 08:00:00 -0400

Common Shares to Trade on the Nasdaq Capital Market Under the Symbol "OPTH" Vancouver, British Columbia--(Newsfile Corp. - May 20, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced the pricing of its underwritten public offering (the " Offering") in connection with the uplisting of its common shares to the Nasdaq...

Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing

Thu, 23 Apr 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that further to its press release dated March 16, 2026, it intends to complete a portion of its previously announced offering of common shares (the "Offering") in Canada pursuant to the Listed Issuer Financing Exemption contained in Part A of...

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

Mon, 20 Apr 2026 06:00:00 -0400

The Company's Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTSD, and traumatic brain injury Vancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today launched its Ibogaine...

Optimi Health startet Ibogaine-Initiative, da US-Executive Order einen Weg für psychedelische Arzneimittelprodukte signalisiert

Mon, 20 Apr 2026 02:00:00 -0400

Die nach GMP lizenzierte Produktionsplattform des Unternehmens mit Health-Canada-Zulassung ist bereit, die entstehende Nachfrage nach Ibogaine zu bedienen - einem natürlich vorkommenden Alkaloid, das zur Behandlung von Opioidkonsumstörungen, PTBS und traumatischen Hirnverletzungen untersucht wird. Vancouver, British Columbia--(Newsfile Corp. - Montag, 20. April 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (das "Unternehmen" oder "Optimi"), ein kommerziell tätiger...

Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering

Mon, 16 Mar 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced that it has commenced an underwritten public offering in the United States (the "Offering") of its common shares, no par value (the "Shares"), pursuant to a registration statement filed with the United States...

Optimi Health berichtet über den frühen klinischen Einsatz natürlicher Psilocybin-Kapseln zur Behandlung therapieresistenter Depressionen in Australien

Thu, 26 Feb 2026 07:00:00 -0500

Erste Patienten im Jahr 2026 außerhalb sponsorengeleiteter klinischer Studien im Rahmen des regulierten australischen Zugangsmodells behandelt Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 26. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller pharmazeutischer Psychedelika-Produkte in pharmazeutischer Qualität, gab heute bekannt, dass in Australien nun Patienten mit...

Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia

Thu, 26 Feb 2026 07:00:00 -0500

First Patients of 2026 Treated Outside of Sponsor-Led Clinical Trials Under Australia's Regulated Framework Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today reported that patients diagnosed with treatment-resistant depression (TRD) have now been treated in Australia using the Company's naturally...